uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

• Status: Terminated
• Trial end date: 2019-10-11
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark
• Treatments: Radium Ra 223 dichloride; Succinylcholine

Criteria

Inclusion Criteria:

• Metastatic castration resistant prostate cancer

• Approved to receive Radium-223 therapy

• Written and oral consent

Exclusion Criteria:

• Lack of communication skills

• Other known malignant disease

• Known allergy towards IMP

• Severe claustrophobia

• If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study